Report of Foreign Issuer (6-k)
November 09 2017 - 8:13AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
under
the Securities Exchange Act of 1934
For
the month of:
November 2017 (Report No. 2)
Commission
file number:
001- 38041
THERAPIX
BIOSCIENCES LTD.
(Translation
of registrant’s name into English)
4
Ariel Sharon Street
HaShahar
Tower, 16th Floor
Givatayim
5320047, Israel
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____
Other
Events
On
November 9, 2017, Therapix Biosciences Ltd. (the “Company”) issued a press release announcing its third quarter financial
results and business update for the quarter ended September 30, 2017 and details of a conference call to be held at 8:30 a.m.
EST on November 9, 2017 to discuss the results and business update. The press release is attached as Exhibit 99.1 and is incorporated
by reference herein. The information contained in Exhibit 99.1 shall not be deemed “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing
under the Securities Act of 1933, as amended, or the Exchange Act, unless expressly set forth by specific reference in such a
filing.
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
Therapix
Biosciences Ltd.
(Registrant)
|
|
|
|
|
By
|
/s/
Josh Blacher
|
|
Name:
|
Josh
Blacher
|
|
Title:
|
Chief
Financial Officer
|
Date:
November 9, 2017
3
Therapix Biosciences (NASDAQ:TRPX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Therapix Biosciences (NASDAQ:TRPX)
Historical Stock Chart
From Apr 2023 to Apr 2024